heart failure glp-1 and the cardiovascular system Cardiovascular disease continuum-GLP-1 action. Adapted

Obesity Clinical Development Pipeline Weight Loss Will early data shown by Lillys Triple G retatrutide (Phase 3) and Amgens AMG-133 (Phase 2) be recapitulated in ongoing studies to demonstrate both faster weight loss and greater total weight loss, compared to approved GLP-1 RA

Participants were White, Black, Caucasian, or of mixed race (Korean/White)

Cardiovascular disease in diabetes and chronic kidney disease

As your weight loss progresses and abdominal fat decreases, you may need to transition to other sites or adjust your technique to maintain proper subcutaneous delivery

[DOI] [PubMed] [Google Scholar] 153.Nicolau J, Tamayo MI, Sanchis P, et al